AstraZeneca to acquire Ardea Bio for $1.26 billion

23 April 2012

In line with its stated policy of making strategic, rather than mega, acquisitions, Anglo-Swedish drug major AstraZeneca (LSE: AZN) revealed this morning that it has entered into a definitive accord with Ardea Biosciences (Nasdaq: RDEA), a San Diego, California-based biotechnology company focused on the development of small-molecule therapeutics.

Under the terms of the agreement, AstraZeneca will acquire Ardea for $32 per share which represents a total cash value of around $1.26 billion, including existing cash (making the cost of the deal around $1 billion). This represents a premium on the value of Ardea’s stock of 50% based on the one month volume-weighted average price (and 54% based on the closing price on Friday, April 20, 2012. Ardea posted a net loss of $86.6 million, or $3.26 a share, for full year 2011.

Deal includes Ph III gout drug lesinurad

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology